FDA Advisory Panel Votes Down Amylyx Pharmaceuticals’ ALS Drug Candidate

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee yesterday declined by a vote of 6-4 to recommend approval of Amylyx Pharmaceuticals’ AMX0035, a drug intended to treat amyotrophic lateral sclerosis (ALS).
Source: Drug Industry Daily